Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025)
Pyxis Oncology's (PYXS) quarterly Cash from Financing Activities came in at $669000.0 in Q4 2025, up 1238.0% year-on-year from $50000.0 in Q4 2024, and up 8462.5% on a QoQ basis from -$8000.0 in Q3 2025.
Pyxis Oncology (PYXS) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 6 years of Cash from Financing Activities data on file, last reported at $669000.0 in Q4 2025.
- On a quarterly basis, Cash from Financing Activities rose 1238.0% year-over-year to $669000.0 in Q4 2025; TTM through Dec 2025 was $2.4 million, a 96.01% decrease from a year earlier, with the FY2025 full-year figure at $594000.0, down 99.0% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $669000.0, up from -$8000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for PYXS reached as high as $154.9 million in Q4 2021 and fell as low as -$1.7 million in Q3 2021.
- Historically, Cash from Financing Activities has averaged $24.3 million across 5 years, with a median of $50000.0 in 2024.
- Across the five-year window, Cash from Financing Activities jumped 15489900.0% in 2021 and sank 2950.0% in 2023, its largest moves.
- Year by year, Cash from Financing Activities stood at $154.9 million in 2021, then sank by 100.0% to $6000.0 in 2022, then plunged by 516.67% to -$25000.0 in 2023, then soared by 300.0% to $50000.0 in 2024, then jumped by 1238.0% to $669000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $669000.0 in Q4 2025, -$8000.0 in Q3 2025, and $50000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,946.26 Bn | 1,946.20 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 473.25 Bn | 468.46 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 123.17 Bn | 115.92 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.54 Bn | 60.79 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - | - |
| 8 | Argenx Se | 56.91 Bn | 51.72 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.23 Bn | 38.23 Bn | - | 238.74 Mn |
| 10 | Pyxis Oncology | 174.00 Mn | 107.14 Mn | 8.65 Mn | 669,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 669,000.00 |
| Dec 31, 2025 | 669,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Dec 31, 2024 | 50,000.00 |
| Sep 30, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 110,000.00 |
| Jun 30, 2024 | 110,000.00 |
| Mar 31, 2024 | 57.51 Mn |
| Mar 31, 2024 | 57.51 Mn |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2023 | -171,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |